11/19/2026 | Press release | Distributed by Public on 11/19/2026 05:00
November 19, 2026
Josef Coufal, our Deputy Head of the Analytical R&D Department, shared insights into Extractables & Leachables, focusing on evolving regulatory guidance, risk assessment, and practical analytical approaches.
On November 10-11, VVKL 2026 brought together specialists in pharmaceutical development, manufacturing and quality control at Aquapalace Prague, Czech Republic.
Our colleague Josef Coufal from the Analytical R&D Department was invited to give a presentation titled Extractables & Leachables: Regulatory Framework and Analytical Approaches.
His presentation connected evolving regulatory guidance with risk-based assessment and practical laboratory experience, highlighting the challenges of identifying and evaluating substances released from materials used in pharmaceutical manufacturing and packaging.
What substances can be released from materials used in pharmaceutical manufacturing and packaging? And what potential risks could they pose to patients?
These fundamental questions form the basis of Extractables & Leachables (E&L) assessments.
Extractables are substances released from materials under controlled laboratory extraction conditions, while leachables are substances that migrate into a pharmaceutical product under actual manufacturing, storage or use conditions.
A structured E&L assessment typically begins with an evaluation of the materials involved and their intended use. Depending on the identified risks, further steps may include extraction studies, identification of unknown compounds, toxicological evaluation and targeted leachables testing.
For a more detailed introduction to these studies, see our earlier article, Problem Packaging: The Next Safety Concern?.
A key part of Josef's presentation focused on the regulatory framework surrounding E&L assessments, including the ICH Q3E draft guideline published in August 2025.
The presentation also covered established guidance such as USP <1663> and <1664> for pharmaceutical packaging systems, USP <665> and <1665> for manufacturing components, and ISO 10993-18 for the chemical characterization of medical devices.
Beyond the regulatory requirements, Josef discussed the analytical challenges involved in detecting and identifying substances with different chemical properties.
Techniques such as headspace GC-MS, GC-MS, LC-MS and ICP-MS provide complementary information, allowing analysts to investigate a broad range of volatile, semi-volatile, non-volatile and elemental substances.
The presentation also addressed the role of analytical evaluation thresholds and the importance of linking analytical findings to toxicological risk assessment.
These topics are closely connected to the work of our Analytical R&D Department, where method development, trace analysis and impurity identification form part of everyday scientific practice.
By combining regulatory perspectives with practical laboratory experience, Josef's presentation contributed to the broader discussion on the challenges and approaches involved in E&L testing.
Would you like to know more? Let us know.
3 September 2026
Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients
New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems
7 August 2026
Quinta-Analytica at CPHI Milan 2026 - Meet Us at Conscio Group Stand 6N25
Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.
15 July 2026
Quinta-Analytica Awarded the EcoVadis Gold Medal
Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.
E-mail: [email protected]
Call: +420 242 454 311 or +420 242 454 300